Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer – final appraisal document

In DRAFT guidance, NICE recommends osimertinib for the treatment of untreated locally advanced or metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer in adults, only if the company provides it according to the commercial arrangement.

Source:

National Institute for Health and Care Excellence